ArticlePituitary2022
Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience.
Article in Pituitary, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Proteomic profile of bone in patients with acromegaly: new insights from a pilot exploratory study.Journal of endocrinological investigation · 2026Article
- Authors' reply to the Comment on Osteometabolic complications in patients with secreting pituitary adenomas: Is there an impact of gender?Pituitary · 2026Article
- Bone and joint quality remains impaired in long-term controlled acromegaly: an HR-pQCT study.Journal of the Endocrine Society · 2026Article
- Acromegaly complications: an update.The Journal of clinical endocrinology and metabolism · 2026Review
- The acromegaly patient experience: burden of treatment and quality of life.The Journal of clinical endocrinology and metabolism · 2026Review
- Osteometabolic complications in patients with secreting pituitary adenomas: Is there an impact of gender?Pituitary · 2026Review
- Consensus on acromegaly complications: an update.Pituitary · 2026Article
- Long-term effect on bone mineral density of denosumab in the treatment of hyperpituitarism driven osteoporosis: an exploratory study.Pituitary · 2026Article
- Association between vertebral fracture risk and bone mineral density in patients with acromegaly.Pituitary · 2025Article
- Osteoporosis and fragility fractures in patients with acromegaly: A two-center cross-sectional study.World journal of orthopedics · 2025Article
- Acromegaly treatment and bone: a bidirectional relationship.Pituitary · 2025Review
- Consensus on acromegaly therapeutic outcomes: an update.Nature reviews. Endocrinology · 2025Review
- Evaluation of bone density and microstructure by DXA, TBS and HR-pQCT: an assessment of cortical porosity and its association with vertebral fractures in patients with acromegaly.Journal of endocrinological investigation · 2025Article
- Early Predictors of Remission in Acromegaly Patients after Pure Endoscopic Endonasal Transsphenoidal Surgery.Journal of neurological surgery. Part B, Skull base · 2025Article
- Evaluation of the relation between subclinical systolic dysfunction defined by four-dimensional speckle-tracking echocardiography and growth differentiation factor-15 levels in patients with acromegaly.Hormones (Athens, Greece) · 2024Article
- Novel approach to bone comorbidity in resistant acromegaly.Pituitary · 2024Review
- Insights from an Italian Delphi panel: exploring resistance to first-generation somatostatin receptor ligands and guiding second-line medical therapies in acromegaly management.Journal of endocrinological investigation · 2024Article
- Review
- New insights into the vitamin D/PTH axis in endocrine-driven metabolic bone diseases.Endocrine · 2024Review
- Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE).Pituitary · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAcromegaly is a chronic disease with systemic complications. Disease onset is insidious and consequently typically burdened by diagnostic delay. A longer diagnostic delay induces more frequently cardiovascular, respiratory, metabolic, neuropsychiatric and musculoskeletal comorbidities. No data are available on the effect of diagnostic delay on skeletal fragility. We aimed to evaluate the effect of diagnostic delay on the frequency of incident and prevalent of vertebral fractures (i-VFs and p-VFs) in a large cohort of acromegaly patients. PATIENTS AND
methodsA longitudinal, retrospective and multicenter study was conducted on 172 acromegaly patients.
resultsMedian diagnostic delay and duration of follow-up were respectively 10 years (IQR: 6) and 10 years (IQR: 8). P-VFs were observed in 18.6% and i-VFs occurred in 34.3% of patients. The median estimated diagnostic delay was longer in patients with i-VFs (median: 11 years, IQR: 3), in comparison to those without i-VFs (median: 8 years, IQR: 7; p = 0.02). Age at acromegaly diagnosis and at last follow-up were higher in patients with i-VFs, with respect to those without i-VFs. The age at acromegaly diagnosis was positively associated with the diagnostic delay (p < 0.001, r = 0.216). A longer history of active acromegaly was associated with a high frequency of i-VFs (p = 0.03). The logistic regression confirmed that patients with a diagnostic delay > 10 years had 1.5-folds increased risk of developing i-VFs (OR: 1.5; 95%CI: 1.1-2; p = 0.017).
conclusionOur data showed that the diagnostic delay in acromegaly has a significant impact on VF risk, further supporting the clinical relevance of an early acromegaly diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.